Latest news

• AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine

  In December 2020, the EC also authorised a CMA for Pfizer/BioNTech’s COVID-19 vaccine, now known as Comirnaty.

• Moderna’s COVID-19 vaccine could offer protection for ‘a couple of years’, says CEO

  It is the second COVID-19 vaccine to receive an EUA from the FDA following Pfizer/BioNTech’s vaccine, which is also approved in the EU under the name Comirnaty.

• Pfizer introduces new logo in a ‘shift from commerce to science’

  Pfizer/BioNTech has also received conditional marketing authorisation for the vaccine in the European Union, under the brand name Comirnaty.

• Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients

  The ‘Vaccine Transition Option’ will offer participants the choice to learn whether they received the investigational vaccine, recently approved in the EU as Comirnaty, or a placebo.

• UPDATED: EU authorises Pfizer/BioNTech's COVID-19 vaccine

  After reviewing the available data, the CHMP adopted a positive opinion of the vaccine, which will now be market as Comirnaty in the EU following the EC authorisation.